Location History:
- Köln, DE (2018)
- Cologne, DE (2020 - 2024)
Company Filing History:
Years Active: 2018-2024
Title: The Innovations of Silke Wissing: A Pioneer in AAV Technology
Introduction
Silke Wissing, an accomplished inventor based in Cologne, Germany, has made significant contributions to the field of biotechnology. With six patents to her name, Wissing has demonstrated her expertise in developing innovative solutions, particularly in the realm of adeno-associated virus (AAV) technology. Her inventions are aimed at enhancing the production and functionality of viral vectors used in gene therapy and other biomedical applications.
Latest Patents
Among her recent patents, Wissing's work on "Inducible AAV REP genes" stands out. This invention pertains to host cells that comprise a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, where the internal AAV promoter p19 has been modified to maintain the functionality of these crucial proteins. This development is critical for the effective production of AAV vectors, which are widely used in therapeutic applications.
Another notable patent by Wissing focuses on the "Use of constitutively active variants of growth factor receptors as selection markers for the generation of stable producer cell lines." This invention outlines methods for selecting stable producer cell lines that express proteins of interest through stable transfection with genes encoding active growth factor receptor variants. This innovative approach streamlines the cultivation and expression processes for therapeutic proteins.
Career Highlights
Silke Wissing has worked with prominent organizations such as Cevec Pharmaceuticals GmbH. Her experiences in these companies have not only enhanced her expertise but also allowed her to contribute to cutting-edge research in biotechnology. Wissing's efforts have led to the realization of practical applications of her patented technologies in various therapeutic contexts.
Collaborations
Throughout her career, Wissing has collaborated with esteemed colleagues including Nicole Faust and Jens Wölfel. These partnerships have facilitated the advancement of her innovative projects, enabling her to push the boundaries of current biotechnological capabilities.
Conclusion
Silke Wissing's contributions to the field of biotechnology exemplify the spirit of innovation that drives advancements in medical science. Her patents, focusing on AAV technology and producer cell line development, are paving the way for enhanced gene therapy solutions. As she continues to collaborate with other experts in the field, Wissing's work is sure to have a lasting impact on the future of biotechnology and therapeutic development.